Supplemental material
Journal of Asthma
Volume 59, 2022 - Issue 1
Open access
3,041
Views
10
CrossRef citations to date
0
Altmetric
Biologics
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
Ling Eng Tana Ministry of Health, Agency for Care Effectiveness, Singapore, Singaporehttps://orcid.org/0000-0001-8140-6210
, MSc, Wan Hui Gloria Tana Ministry of Health, Agency for Care Effectiveness, Singapore, Singaporehttps://orcid.org/0000-0001-5168-536X
, MPH, Mohamed Ismail Abdul Aziza Ministry of Health, Agency for Care Effectiveness, Singapore, Singaporehttps://orcid.org/0000-0003-3606-7672
, MSc, Mariko Siyue Kohb Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore;c Office of Clinical, Academic and Faculty Affairs, Duke NUS Medical School, Singapore, Singaporehttps://orcid.org/0000-0002-1230-0129
, MBBS, MRCP, Tunn Ren Tayd Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore, Singaporehttps://orcid.org/0000-0001-5729-647X
, MBBS, MRCP, FAMS, Fiona Pearcea Ministry of Health, Agency for Care Effectiveness, Singapore, Singapore
, MPH & Kwong Nga Ministry of Health, Agency for Care Effectiveness, Singapore, SingaporeCorrespondence[email protected]
https://orcid.org/0000-0002-6511-1639
, MClinPharm, MPH show allhttps://orcid.org/0000-0002-6511-1639
Pages 189-199
|
Received 09 Jun 2020, Accepted 11 Oct 2020, Published online: 10 Nov 2020
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.